To date, there is no pathological or etiological indication that RD3 gene expression plays a role in GBM development or disease progression, but current public datasets such as TCGA (https://www.cancer.gov/tcga) provide useful information about hypothetical correlations of RD3 transcript levels and their impact in specific diseases. The gene discussed is RD3; the disease is glioblastoma.